Article

Pathway-selective strategies reveal specific PI3K–mTOR inhibitors as key partners in KRAS G12D-targeted therapy

2025-10-06

Abstract excerpt

<title>Abstract</title> <p>KRAS G12D is the most common oncogenic mutation in pancreatic ductal adenocarcinoma (PDAC), driving resistance and heterogeneity. Using robotic high-throughput drug screening with live-cell imaging, we evaluated normalized organoid growth rate (NOGR) in KRAS G12D-mutant PDAC organoids treated with the inhibitor MRTX1133. Monotherapy induced predominantly cytostatic, dose-dependent effec...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: e5cf989f-5266-53c4-be7b-b8b51261a003
DOI: 10.21203/rs.3.rs-7614104/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Pathway-selective strategies reveal specific PI3K–mTOR inhibitors as key partners in KRAS G12D-targeted therapyDOI 10.21203/rs.3.rs-7614104/v1Read

Patient-derived organoids guide personalized therapy for KRAS-mutant pancreatic cancer: synergistic MEK/mTOR inhibition and predictive chemotherapy responses.Semantic proximity Read

Molecular dissection of pancreatic cancer signaling: Toward targeted therapies for KRAS, MDM2-TP53, EGFR, and PI3K/AKT/mTOR.Semantic proximity Read

KRASG 12C-inhibitor-based combination therapies for pancreatic cancer: insights from drug screening.Semantic proximity Read

Altered PI3K and ERK/MAPK Signaling in KRASG12R-Driven Pancreatic Cancer Presents Opportunities for Precision Therapy.Semantic proximity Read

Cell-specific models reveal conformation-specific RAF inhibitor combinations that synergistically inhibit ERK signaling in pancreatic cancer cellsSemantic proximity Read

A Genome-scale CRISPR Screen Identifies the ERBB and mTOR Signaling Networks as Key Determinants of Response to PI3K Inhibition in Pancreatic CancerSemantic proximity Read

Overcoming Daraxonrasib Resistance: Allele-Specific Mechanisms Guide Salvage Therapy in Pancreatic CancerSemantic proximity Read

The PI3K-AKT-mTOR axis persists as a therapeutic dependency in KRAS <sup>G12D</sup> -driven non-small cell lung cancerSemantic proximity Read

Pharmacologically targeting KRAS <sup>G12D</sup> in PDAC models: tumor cell intrinsic and extrinsic impactSemantic proximity Read

Organoid Pharmacotyping of Pancreatic Cancer Enables Functional Precision Oncology and Drug RepurposingSemantic proximity Read

Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant Cancers.Semantic proximity Read

A pancreatic cancer organoid platform identifies an inhibitor specific to mutant KRAS.Semantic proximity Read